Valuation: FunPep Company Limited

Market Cap 3.45B 21.05M 18.51M 17.23M 15.82M 29.71M 2.02B 30.1M 205M 79.97M 997M 79.02M 77.32M P/E 2024
-4.22x
P/E 2025 -1.63x
Enterprise Value 1.68B 10.25M 9.01M 8.39M 7.7M 14.46M 983M 14.65M 99.69M 38.93M 485M 38.47M 37.64M EV / Sales 2024
338x
EV / Sales 2025 -
Free-Float
79.81%
Yield 2024 *
-
Yield 2025 -
03-08 FunPep Company Limited announced that it has received ¥32.5315 million in funding from Next Growth Co., Ltd., Growth Capital, Inc. CI
02-19 FunPep Company Limited announced that it expects to receive ¥32.5315 million in funding from Next Growth Co., Ltd., Growth Capital, Inc. CI
25-03-09 FunPep Company Limited announced that it has received ¥3.6 million in funding from SBI Securities Co., Ltd. CI
25-02-20 FunPep Company Limited announced that it expects to receive ¥3.6 million in funding from SBI Securities Co., Ltd. CI
24-07-21 FunPep Company Limited announced that it has received ¥3.52 million in funding from SBI SECURITIES Co., Ltd. CI
24-07-04 FunPep Company Limited announced that it expects to receive ¥3.52 million in funding from SBI SECURITIES Co., Ltd. CI
24-03-20 FunPep Company Limited announced that it has received ¥199.9998 million in funding from Shionogi & Co., Ltd. CI
24-03-03 FunPep Company Limited announced that it expects to receive ¥199.9998 million in funding from Shionogi & Co., Ltd. CI
23-11-14 FunPep Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
23-05-15 FunPep Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
22-09-30 FunPep Company Limited completed the acquisition of Anti-Aging Peptide Co., Ltd. from Hironori Nakagami , Bio Site Start Fund L.P., Naotaka Hashiya, Chiyako Ueda, ReBeage Co., Ltd. and others. CI
22-07-13 FunPep Company Limited agreed to acquire Anti-Aging Peptide Co., Ltd. from Hironori Nakagami , Bio Site Start Fund L.P., Naotaka Hashiya, Chiyako Ueda, ReBeage Co., Ltd. and others. CI
21-12-12 FunPep Company Limited announced that it has received ¥3.741 million in funding from SBI Securities Co., Ltd., Investment Arm CI
1 day-22.06%
1 week-22.06%
Current month-13.11%
1 month-13.11%
3 months-24.29%
6 months-39.08%
Current year-35.37%
1 week 51
Extreme 51
68
1 month 51
Extreme 51
76
Current year 51
Extreme 51
130
1 year 51
Extreme 51
130
3 years 51
Extreme 51
325
5 years 51
Extreme 51
477
10 years 51
Extreme 51
843
Manager TitleAgeSince
Director of Finance/CFO 53 2015-04-30
President 62 2019-12-31
Chief Tech/Sci/R&D Officer 54 2015-06-30
Director TitleAgeSince
Chairman 78 2015-02-28
Director/Board Member 62 2015-02-28
Director/Board Member 54 2015-11-30
Date Insider Type Main position Quantity % Market Cap.
4/28/25
Sola KK
OthersCompany 20,000 0.0617%
4/28/25
Sola KK
OthersCompany 50,000 0.1543%
4/28/25 Others 40,000 0.1234%
Change 5-day change 1-year change 3-year change Capi.($)
-22.06%-22.06%-51.38%-70.22% 20.12M
+2.08%-0.99%-1.34%+11.57% 46.86B
-0.61%+4.26%+396.16%+647.20% 40.23B
0.00%+4.93%+11.81%+55.56% 36.23B
+2.48%+4.57%+7.05%-5.05% 34.72B
+0.62%+3.53%+5.41%+42.19% 27.89B
-2.00%+11.64%+31.71%+136.81% 16.79B
-0.17%+0.66% - - 16.74B
+0.78%-5.88%-2.68%+7.76% 13.12B
+1.82%+1.56%-9.75%-30.15% 12.7B
Average -1.71%+1.67%+43.00%+88.41% 24.53B
Weighted average by Cap. +0.70%+1.89%+74.69%+138.29%

Financials

2024 2025
Net sales 6M 36.66K 32.23K 30K 27.55K 51.73K 3.52M 52.42K 357K 139K 1.74M 138K 135K -
Net income -889M -5.43M -4.78M -4.44M -4.08M -7.67M -521M -7.77M -52.83M -20.64M -257M -20.39M -19.95M -1.91B -11.68M -10.26M -9.55M -8.77M -16.48M -1.12B -16.69M -114M -44.36M -553M -43.83M -42.89M
Net Debt -2.35B -14.33M -12.6M -11.73M -10.77M -20.23M -1.37B -20.49M -139M -54.45M -679M -53.81M -52.65M -1.77B -10.8M -9.5M -8.84M -8.12M -15.24M -1.04B -15.45M -105M -41.04M -512M -40.55M -39.68M
Logo FunPep Company Limited
FunPep Co Ltd is a Japan-based company engaged in the research and development business for pharmaceuticals. The main business is to promote research and development of functional peptides, which are the results of research at the Graduate School of Medicine, Osaka University, and to put them into practical use in the business fields such as pharmaceuticals, cosmetics and medical devices. The business model defines its technical area as a functional peptide-based area and a related area that has synergies with it. The Research & Development pipeline is composed of research themes for antibody-inducing peptides and developed products. The Company is engaged in the sale of peptide active ingredients through cosmetic raw material trading companies or sales companies.
Employees
15
Date Price Change Volume
26-07-27 JP¥53.00 -22.06% 2,154,500
26-07-27 JP¥68.00 +4.62% 105,600
26-07-24 JP¥65.00 -4.41% 158,500
26-07-23 JP¥68.00 +1.49% 70,300
26-07-22 JP¥67.00 -1.47% 162,300

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4881 Stock